Opus Genetics Inc. (NASDAQ: IRD) announced initial clinical data from its Phase 1/2 study of OPGx-BEST1 gene therapy at the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE